Introducing the Parsortix®PC1 system - the first medical device to receive FDA clearance for the harvest of intact CTCs
Discover moreEnabling specialised circulating tumour cell (CTC) enrichment and downstream analysis within your laboratory
Discover moreOur laboratory provides specialized circulating tumor cell (CTC) enrichment and analysis services
Discover moreLatest report
Interim Report June 2023
Please click the links below to download our Annual and Interim Reports and Financial Statements
Open PDFFor any investor relations queries please contact
investor@angleplc.comFor any investor relations queries please contact
investor@angleplc.comInvestor relations
Corporate responsibility report